- Business Wire•19 days ago
Oragenics, Inc. , a clinical stage biotechnology company advancing lantibiotics to treat serious bacterial infections and biotherapeutics to treat oral mucositis , today issued a shareholder update from CEO Alan Joslyn outlining the Company’s vision and strategic growth strategy and highlights the significant accomplishments in 2016.
- Business Wire•last monthOragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development
Oragenics , a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it presented at the American Society for Microbiology Conference on Antibacterial Development held at the Omni Shoreham Hotel in Washington, DC, on Dec.
- Investopedia•2 months ago
Oragenics’ key drug AG013 secured Fast Track designation from the FDA for oral mucositis.
OGEN : Summary for Oragenics, Inc. Common Stock - Yahoo Finance
Oragenics, Inc. (OGEN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.65 - 0.70|
|52 Week Range||0.33 - 1.20|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-2.25|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|